These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 22070627)
1. Bifunctional μ/δ opioid peptides: variation of the type and length of the linker connecting the two components. Ding J; Lemieux C; Chung NN; Schiller PW Chem Biol Drug Des; 2012 Feb; 79(2):186-93. PubMed ID: 22070627 [TBL] [Abstract][Full Text] [Related]
3. N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile. Weltrowska G; Nguyen TM; Chung NN; Wilkes BC; Schiller PW Bioorg Med Chem Lett; 2013 Sep; 23(18):5082-5. PubMed ID: 23932788 [TBL] [Abstract][Full Text] [Related]
4. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285 [TBL] [Abstract][Full Text] [Related]
5. The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. Schiller PW; Weltrowska G; Berezowska I; Nguyen TM; Wilkes BC; Lemieux C; Chung NN Biopolymers; 1999; 51(6):411-25. PubMed ID: 10797230 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. Balboni G; Guerrini R; Salvadori S; Bianchi C; Rizzi D; Bryant SD; Lazarus LH J Med Chem; 2002 Jan; 45(3):713-20. PubMed ID: 11806723 [TBL] [Abstract][Full Text] [Related]
7. Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. Tóth G; Ioja E; Tömböly C; Ballet S; Tourwé D; Péter A; Martinek T; Chung NN; Schiller PW; Benyhe S; Borsodi A J Med Chem; 2007 Jan; 50(2):328-33. PubMed ID: 17228874 [TBL] [Abstract][Full Text] [Related]
8. Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. Balboni G; Onnis V; Congiu C; Zotti M; Sasaki Y; Ambo A; Bryant SD; Jinsmaa Y; Lazarus LH; Trapella C; Salvadori S J Med Chem; 2006 Sep; 49(18):5610-7. PubMed ID: 16942034 [TBL] [Abstract][Full Text] [Related]
9. From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. Balboni G; Cocco MT; Salvadori S; Romagnoli R; Sasaki Y; Okada Y; Bryant SD; Jinsmaa Y; Lazarus LH J Med Chem; 2005 Aug; 48(17):5608-11. PubMed ID: 16107162 [TBL] [Abstract][Full Text] [Related]
10. Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism. Salvadori S; Guerrini R; Balboni G; Bianchi C; Bryant SD; Cooper PS; Lazarus LH J Med Chem; 1999 Dec; 42(24):5010-9. PubMed ID: 10585210 [TBL] [Abstract][Full Text] [Related]
11. Bioactivity of new mu and delta opioid peptides. Capasso A Med Chem; 2007 Sep; 3(5):480-7. PubMed ID: 17897075 [TBL] [Abstract][Full Text] [Related]
13. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity. Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674 [TBL] [Abstract][Full Text] [Related]
14. Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Salvadori S; Attila M; Balboni G; Bianchi C; Bryant SD; Crescenzi O; Guerrini R; Picone D; Tancredi T; Temussi PA Mol Med; 1995 Sep; 1(6):678-89. PubMed ID: 8529134 [TBL] [Abstract][Full Text] [Related]
15. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism. Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245 [TBL] [Abstract][Full Text] [Related]
16. Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists. Schiller PW; Nguyen TM; Weltrowska G; Wilkes BC; Marsden BJ; Lemieux C; Chung NN Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11871-5. PubMed ID: 1334552 [TBL] [Abstract][Full Text] [Related]
17. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists. Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Lu Y Life Sci; 2003 Jun; 73(6):691-8. PubMed ID: 12801590 [TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of dermorphin analogues containing N-substituted amino acids in the 2-position of the peptide sequence. Schmidt R; Kálmán A; Chung NN; Lemieux C; Horváth C; Schiller PW Int J Pept Protein Res; 1995 Jul; 46(1):47-55. PubMed ID: 7558596 [TBL] [Abstract][Full Text] [Related]
19. Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. Li T; Fujita Y; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Salvadori S; Lazarus LH; Okada Y J Med Chem; 2005 Dec; 48(25):8035-44. PubMed ID: 16335927 [TBL] [Abstract][Full Text] [Related]